Fig. 2.

Analysis of the efficacy, net benefit, and clinical utility of Proclarix, PSA density, and the ERSPC MRI predictive model for detection of clinically significant prostate cancer in men with a PI-RADS 3 lesion. (A) Receiver operating characteristic curves and area under the (AUC), (B) decision curve analysis, and (C) clinical utility curves. PSA = prostate-specific antigen; ERSPC = European Randomized Study of Screening for Prostate Cancer; MRI = magnetic resonance imaging; PI-RADS = Prostate Imaging-Reporting and Data System.